Dr. Kaimakliotis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
535 Barnhill Dr
Indianapolis, IN 46202Phone+1 317-944-4628Fax+1 317-944-0174
Education & Training
- Yale-New Haven Medical CenterResidency, Urology, 2008 - 2012
- Yale School of MedicineClass of 2007
Certifications & Licensure
- IN State Medical License 2013 - 2025
- CT State Medical License 2012 - 2013
- American Board of Urology Urology
Clinical Trials
- A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer Start of enrollment: 2022 Mar 01
Roles: Contact
Publications & Presentations
PubMed
- Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel.Phillip M Pierorazio, Nir Kleinmann, Ahmad Shabsigh, Brian Hu, Jay D Raman
The Journal of Urology. 2025-03-01 - Durability of response of UGN-101: Longitudinal follow up of multicenter study.Solomon L Woldu, Daniel Igel, Brett Johnson, Katie S Murray, Hiroko Miyagi
Urologic Oncology. 2025-01-20 - 1 citationsUnbiased discovery of cancer pathways and therapeutics using Pathway Ensemble Tool and Benchmark.Luopin Wang, Aryamav Pattnaik, Subhransu Sekhar Sahoo, Ella G Stone, Yuxin Zhuang
Nature Communications. 2024-08-24
Authored Content
- Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future PerspectivesSeptember 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: